Edward H. Myles Sells 7,809 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) CFO Edward H. Myles sold 7,809 shares of Scholar Rock stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $287,605.47. Following the completion of the transaction, the chief financial officer now owns 140,740 shares in the company, valued at approximately $5,183,454.20. The trade was a 5.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Scholar Rock Stock Performance

Shares of SRRK opened at $39.15 on Friday. The firm’s 50-day moving average price is $41.89 and its 200-day moving average price is $28.17. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 1-year low of $6.76 and a 1-year high of $46.98.

Institutional Investors Weigh In On Scholar Rock

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in shares of Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after purchasing an additional 269 shares in the last quarter. Global Retirement Partners LLC boosted its stake in shares of Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after purchasing an additional 766 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock valued at $48,000 after purchasing an additional 1,031 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Scholar Rock during the 4th quarter valued at about $85,000. Finally, Amalgamated Bank boosted its stake in Scholar Rock by 30.6% during the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock worth $114,000 after acquiring an additional 620 shares in the last quarter. Institutional investors own 91.08% of the company’s stock.

Analyst Upgrades and Downgrades

SRRK has been the topic of a number of analyst reports. HC Wainwright lifted their target price on shares of Scholar Rock from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Truist Financial raised their price target on shares of Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, November 25th. Finally, Wedbush reissued an “outperform” rating and issued a $47.00 price target on shares of Scholar Rock in a report on Wednesday, January 29th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Scholar Rock presently has a consensus rating of “Buy” and an average price target of $40.43.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.